Semaglutide and tirzepatide are both injectable medications used to support weight loss and metabolic health, but they don't work the same way. Understanding the difference helps set realistic expectations.
Semaglutide
- Acts on a single receptor — GLP-1
- Strong appetite suppression and improved glucose control
- Studied for years for type 2 diabetes (Ozempic) and weight management (Wegovy)
- Average weight loss in clinical studies: roughly 12–15% of body weight over a year
Tirzepatide
- Acts on two receptors — GLP-1 and GIP
- Often produces stronger appetite reduction and greater weight loss
- Marketed as Mounjaro (diabetes) and Zepbound (weight management)
- Average weight loss in clinical studies: roughly 18–22% of body weight at higher doses
How to think about choosing
Bigger results in a trial don't automatically mean a better fit for you. Tolerance, side effect profile, cost, dosing flexibility, and your medical history all shape the right choice. Many clients respond well to either; others tolerate one much better than the other.
This is a clinical decision, not a search-engine decision. A consultation reviews your labs, history, and goals so the recommendation is genuinely tailored.